PMS2 is one of the four susceptibility genes in Lynch syndrome (LS), the most common cancer syndrome in the world. Inherited mutations in DNA mismatch repair (MMR) genes, MLH1, MSH2, and MSH6, account for approximately 90% of LS, while a relatively small number of LS families segregate a PMS2 mutation. This and the low cancer penetrance in PMS2 families suggest that PMS2 is only a moderate or low-risk susceptibility gene. We have previously shown that even a partial expression decrease in MLH1, MSH2, or MSH6 suggests that heterozygous LS mutation carriers have MMR malfunction in constitutive tissues. Whether and how PMS2 expression decrease affects the repair capability is not known. Here, we show that PMS2 knockdown cells retaining 19%, 33%, or 53% of PMS2 expression all have significantly reduced MMR efficiency. Surprisingly, the cells retaining expression levels comparable to PMS2 mutation carriers indicate the lowest repair efficiency. repair malfunction, which is the cause of early-onset colorectal and endometrial cancers and less frequently cancer of the ovaries, stomach, pancreas, prostate, and breast in LS families (Lynch et al., 2015) . However, in PMS2 families the prevalence of stomach, prostate, and breast cancers is unusually high and compared to MLH1 and MSH2 families, also the mean age of cancer onset is higher and the penetrance of colorectal and endometrial cancers lower, resembling the situation in MSH6 families (Hendriks et al., 2006; Roberts et al., 2018; Senter et al., 2008; ten Broeke et al., 2015; Truninger et al., 2005) . One explanation for the lower cancer penetrance in PMS2 families might be the protein homologue MLH3, which is also able to bind and partially function with MLH1 (Cannavo et al., 2005; Korhonen, Raevaara, Lohi, & Nystrom, 2007; Senter et al., 2008; ten Broeke et al., 2015) .
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As a component of the MutLα (MLH1 + PMS2) heterodimer, PMS2 (postmeiotic segregation increased 2) is central in the postreplicative human DNA mismatch repair (MMR) mechanism (Kunkel & Erie, 2005) . Heterozygous germline mutations in MMR genes cause Lynch syndrome (LS; MIM# 120435), the most common cancer predisposition syndrome in human (de la Chapelle, 2004; Lynch, Snyder, Shaw, Heinen, & Hitchins, 2015) . Mutations in MLH1 (MIM# 120436) and MSH2 (MIM# 609309) are the most prevalent in known LS families (36.2% and 35.3%, respectively), while the number of MSH6 (MIM# 600678) and PMS2 (MIM# 600259) mutations is lower (19.4% and 9.1%, respectively; www.insight-database.org, data accessed January 22, 2019). The absence of functional MMR protein results in DNA repair malfunction, which is the cause of early-onset colorectal and endometrial cancers and less frequently cancer of the ovaries, stomach, pancreas, prostate, and breast in LS families (Lynch et al., 2015) . However, in PMS2 families the prevalence of stomach, prostate, and breast cancers is unusually high and compared to MLH1 and MSH2 families, also the mean age of cancer onset is higher and the penetrance of colorectal and endometrial cancers lower, resembling the situation in MSH6 families (Hendriks et al., 2006; Roberts et al., 2018; Senter et al., 2008; ten Broeke et al., 2015; Truninger et al., 2005) . One explanation for the lower cancer penetrance in PMS2 families might be the protein homologue MLH3, which is also able to bind and partially function with MLH1 (Cannavo et al., 2005; Korhonen, Raevaara, Lohi, & Nystrom, 2007; Senter et al., 2008; ten Broeke et al., 2015) .
The diagnostic workflow to identify Lynch syndrome typically involves tumor studies and DNA analyses. The first clinical step in diagnosing LS includes tumor immunohistochemistry (IHC) and microsatellite instability (MSI) analyses followed by mutation screening dictated by the IHC and MSI results (Kansikas, Kariola, & Nystrom, 2011; Yurgelun & Hampel, 2018) . While IHC is a valuable method for distinguishing PMS2 carriers, who generally lose only PMS2, from MLH1 carriers, who frequently lose both MLH1 and PMS2 protein expressions in a tumor (Niessen et al., 2009) , it took a decade to differentiate sequence between PMS2 and its 15 pseudogenes for reliable sequencing and mutation detection (De Vos, Hayward, Picton, Sheridan, & Bonthron, 2004; van der Klift et al., 2010; Vaughn et al., 2010) . As an outcome, the prevalence of PMS2 mutations in suspected LS families has increased according to the InSiGHT database, from approximately 2-9% during the last two decades (www.insight-database.org). Furthermore, the population-based PMS2 variant prevalence was recently reported to be relatively high (1:714) compared to the variant prevalence in MLH1 (1:1946) and MSH2 (1:2841; Win et al., 2017) and a strikingly high prevalence (96%) was reported from an Icelandic population using whole genome sequencing data of a colorectal cancer cohort (Haraldsdottir et al., 2017) .
Nevertheless, atypical clinical phenotypes and a low cancer penetrance in PMS2 families still question its role in Lynch syndrome.
Hence, this study aimed to determine the significance of PMS2 as an LS susceptibility gene by analyzing whether a partial PMS2 expression decrease, compared to the expression decrease in a Lynch syndrome mutation carrier, causes mismatch repair malfunction, as was previously shown to be the case with the susceptibility genes MLH1, MSH2, and MSH6. To be able to assess the repair efficiency of each clone, the nuclear proteins of the cells in chosen clones and their controls were extracted in parallel as described previously (Holmes, Clark, & Modrich, 1990; Kantelinen et al., 2010) . The nuclear protein expression was analyzed by western blot analysis (WB; Supporting Information Materials, Materials & Methods; Figure 1 ). Despite the semiquantitative nature of the method, each KD clone clearly showed decreased PMS2 protein expression compared to the level in its respective control (NC), indicating that the amount of protein reflects the reduced mRNA expression in the cell extract. Importantly, the MLH1 protein expression was shown to be normal in the KD extracts.
For a long time, PMS2 mutation prevalence was underestimated, suggesting that PMS2 is not an important LS susceptibility gene. Its significance in LS has been questioned by the atypically low cancer penetrance in PMS2 families (Senter et al., 2008; ten Broeke et al., 2015) , an unclear risk for extra-colonic cancers (Roberts et al., 2018;  while their controls showed 38%, 55%, and 48% of repair capability, respectively (P = 0.002, 0.001, and 0.0002; Figure   2a ). Interestingly, the most severe repair defect was in cells retaining 53% of PMS2 expression. The relative repair efficiencies (RR%) of cells retaining 19%, 33%, and 53% of PMS2 mRNA expression were 55%, 27%, and 25%, respectively (Figure 2b ), confirming the finding that the KD cells with 53% PMS2 expression had the lowest repair capability.
Previously, a significant reduction in MMR efficiency was detected in cells retaining 75% of MSH6, 50% of MSH2, and 25% of MLH1 mRNA expression (Kansikas et al., 2014) . In this study, we show that PMS2 expression decrease also affects MMR capability but unexpectedly in a different way than what was observed with the other MMR genes. Surprisingly, the lower PMS2 expression levels (19% and 33%) had higher repair efficiencies than the carrier-like level (53%), while in MLH1 and MSH2, 25% expression level was not enough to maintain any repair capability (25% level in MSH6 was not studied; Kansikas et al., 2014) . The severity of MLH1 and MSH2 expression decrease may be due to their obligatory roles in the heterodimeric protein complexes (Acharya et al., 1996; Kondo, Horii, & Fukushige, 2001 ), while such a low level of PMS2 may be compensated by some homologous protein. Compensation of MutLα with MutLγ (MLH1 + MLH3) has been suggested to explain the low penetrance of PMS2 mutations (Cannavo et al., 2005; Korhonen et al., 2007) . Although PMS2 is the main partner of MLH1 among MutL homologues, MutLγ has shown at least low MMR capability (Cannavo et al., 2005; Raschle, Marra, Nystrom-Lahti, Schar, & Jiricny, 1999) .
The nuclear localization of MLH3 seems to be dependent on the absence of PMS2 in the cell (Korhonen et al., 2007) , and while excess of MLH3 has been shown to reduce PMS2 binding to MLH1, most probably MLH3 is not a significant counterpart to MLH1 in a normal cell due to the 60-fold higher expression of PMS2 (Cannavo et al., 2005; Kondo et al., 2001) . To determine whether MLH3 could compensate MMR efficiency in 19% and 33% PMS2 KD clones and improve their repair capability compared to the 53% clone, we further studied MLH3 mRNA expression and protein expression in the clones. Although, the MLH3 mRNA expression levels were decreased, they did not differ between the KD cells ( Figure S1 ), even though slightly lowered MLH3 protein expression in 53% KD clone compared to 19% clone was detected by WB ( Figure S2 ). While MLH3 expression differences do not explain the lowered MMR efficiency in KD clones, it is still possible that the cells expressing only 19% or 33% of PMS2 are able to activate a "survival mechanism" that sustains MMR capability.
By using a functional approach to assess the significance of PMS2 in Lynch syndrome, we show that PMS2 expression decrease causes severe problems in mismatch repair, which is the hallmark of LS susceptibility genes.
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